As a global leader in diabetes technology,
serving millions of people, we are committed to
helping people with diabetes improve their health and
quality of life through our industry-leading
products and solutions.
Robert Schumm
Corporate Officer, PHC Holdings /
President and CEO, Ascensia Diabetes Care
Message
Today, more than one in 10 adults in the world (540 million people) are living with diabetes.*1 At Ascensia, our mission is to make a positive difference for people living with the condition and we have been at the forefront of diabetes innovation for more than 80 years.
Our sole focus on diabetes means that we have a deep appreciation for the needs of people with diabetes, which enables us to develop, manufacture, and deliver innovative products that can help make life with diabetes more manageable. From our high-precision glucose monitoring systems to our digital diabetes management solutions, we provide tools to empower people to better manage their diabetes.
*1 https://diabetesatlas.org/
Brian Hansen
President CGM, Ascensia Diabetes Care
Message
Continuous glucose monitoring (CGM) is transforming diabetes care, significantly reducing the burden faced by people with the condition. We’re proud to be at the forefront of this innovation.
Developed by Senseonics, our Eversense® E3 CGM System is the longest-lasting CGM available, offering six months of continuous glucose readings. This unique capability significantly reduces interruptions, ensuring that users receive the consistent data needed for optimal diabetes management.
We are dedicated to advancing CGM technology to provide solutions that offer reliability, flexibility and empowerment to individuals living with diabetes, helping them manage their condition more effectively and improve their quality of life.
Main Customers
- People with Diabetes
- Healthcare Professionals
- Dispensing Pharmacies
Overview
In our Diabetes Management business, we offer high-quality blood glucose monitoring (BGM) systems, continuous glucose monitoring (CGM) systems, and digital diabetes management solutions that meet the diverse needs of people living with diabetes.
Our world-renowned CONTOUR® range of BGM systems is known for its remarkable accuracy and ease of use, enabling people with diabetes to easily get the data they need to make informed treatment or lifestyle decisions. Since launching the industryʼs first personal BGM in 1981, we have continuously evolved our BGM product offering through innovation and manufacturing excellence, and we are proud to offer the highest level of accuracy*2 in the industry, at a competitive cost.
Developed by our partner Senseonics, the Eversense® CGM System represents a groundbreaking advancement in diabetes technology, as the industryʼs first and only long-term CGM system with an implantable sensor. The system allows continuous measurement of glucose levels, with data automatically sent every five minutes to a mobile app on the userʼs smartphone.
Unlike any other CGMs on the market, the Eversense® sensor can be used continuously for up to six months. Sensors of other available CGM systems are short-term and need to be replaced every seven to 14 days.
Senseonics also has an exciting pipeline of further CGM innovations that we will bring to people with diabetes in the future, including a 365-day Eversense® sensor that has been submitted to the U.S. FDA for review. This further increase in sensor longevity would be a significant milestone for the diabetes industry.
This business has been committed to supporting people with diabetes for more than 80 years and has been responsible for many firsts in diabetes technology. Looking ahead, we will continue to push the boundaries in diabetes management solutions as we aim to simplify and improve life for millions of people.
*2 Pleus S. et al.User Performance Evaluation and System Accuracy of Four Blood Glucose Monitoring System With Color Coding of Measurement Results. 2022
Strengths
- Global business operations and expertise
Our products are sold in more than 100 countries and are used by an estimated 10 million people. We respond to customer needs around the world through our experienced global sales network.
- High-quality, high-precision, cost-competitive products
Our BGM products are manufactured in facilities using state-of-the-art equipment. Optimized product technology and production processes enable us to achieve the industryʼs highest standards of precision and reliability, while maintaining low-cost manufacturing.
- Innovative products/advanced technology
We support more effective self-management of diabetes through innovative products and digital solutions. The Eversense® E3 CGM System provides users with unparalleled reliability and flexibility, the longest-lasting sensor available, and a removable transmitter*3 with on-body vibratory alerts, including for high and low glucose values. Our BGM products are considered among the most accurate available, enabling people to identify blood glucose fluctuations with precision, and empowering them to make confident treatment and lifestyle decisions.
*3 There is no glucose data generated when the transmitter is removed.
Employee Voices
Our Commitment to the Diabetes Community
At Ascensia, we are passionate about diabetes. We’re proud that our products make a difference for people with diabetes every day, but we take even more pride in being a trusted member of the diabetes community. By being truly connected with those who live with the condition, we can make the most impact as a business. Our strong company culture, lived daily by our purpose-driven colleagues, significantly influences why people choose to work for us. Treating our team members with utmost respect, being forward thinking, and trusting each other are core values we are proud of. Over the years, we’ve actively supported various community initiatives that are advocating, educating, and striving to make a better world for those living with diabetes. As part of our commitment to the diabetes community, we are proud to engage with various awareness campaigns and educational initiatives. One example is our work for World Diabetes Day, an annual global awareness initiative from the International Diabetes Federation. Our most recent campaign was a three-year art and photography competition that gave people living with the condition a platform to highlight the real-life struggles and successes of life with diabetes. We had more than 800 submissions from more than 40 countries, and were able to donate €32,000 to charities supporting the diabetes community.
Each year, we have been blown away by the powerful stories and the artistic expression of this global community. These campaigns are important to our employees and demonstrate the passion there is at Ascensia for having a positive impact on the people we serve.
Head of Corporate Communications,
Ascensia Diabetes Care (Basel, Switzerland)Lorraine Chandler
Main Products/Services
Our highly accurate glucose monitoring systems, designed for ease of use by people with diabetes, are used by an estimated 10 million people around the world. Through our integrated diabetes management technology platform, we provide solutions that help people use data to effectively manage diabetes.
-
Blood Glucose Monitoring (BGM) Systems
People with diabetes can easily and accurately measure their blood glucose levels at home.
Systems allow users to sync data with smartphones and other devices.
-
Digital Diabetes Management Solutions
Integrated diabetes management solutions that support more effective self-management and data sharing. GlucoContro.online*4 offers a quick and easy way for people with diabetes to remotely share their blood glucose readings with their healthcare professionals.
-
Continuous Glucose Monitoring (CGM) Systems
Systems continuously measure glucose levels using the world's first fully implantable subcutaneous sensor that can be worn for up to six months. Able to notify users of rises and falls in glucose levels, with a removable transmitter*3 and the ability to provide unique on-body vibratory alerts.
*4 SdNcenter is the legal manufacturer and developer of GlucoContro.online and is partnering with Ascensia to market and deliver the tool to HCP and patient users
Ascensia (BGM/CGM Division)
Market
The glucose monitoring market for diabetes is expanding, but a shift from Blood Glucose Monitoring (BGM) to Continuous Glucose Monitoring (CGM) is in progress, particularly in Europe and the United States.
Strategy
While continuing to enhance focused segments within BGM, we are investing heavily in growth areas centered on CGM. Specifically, for BGM, we seek to maintain profitability by increasing sales in growth segments such as the over-the-counter drug sales channel in the United States, and by introducing low-priced products in some markets, while expanding our market share in mature markets.
We have defined CGM as one of our Growth Areas and are focused on strengthening this business. We will accelerate growth by increasing sales of the Senseonics Eversense® CGM System.
About CGM
The Eversense® CGM System, which we exclusively distribute, is the industryʼs first and only long-term CGM system with an implantable sensor and allows continuous measurement of glucose levels, with data automatically sent every five minutes to a mobile app on the userʼs smartphone. Unlike any other CGM on the market, the Eversense® E3 sensor can be used continuously for up to six months. Sensors of other available CGM systems are short-term and need to be replaced every seven to 14 days.
In addition, our partner Senseonics announced on May 13, 2024 that it has filed a submission with the U.S. FDA for clearance of the next-generation Eversense 365-day system for iCGM designation*5. This potential advance would double the sensor lifetime of an already differentiated product proposition, representing a significant milestone for the diabetes industry.
*5 Senseonics Holdings, Inc. Reports First Quarter 2024 Financial Results – Senseonics
What’s new
Developed by Senseonics, the Eversense® CGM System is highly differentiated from other products as the longest-lasting CGM system available.
It’s been a strong year of progress for Eversense. The Eversense® system recently received iCGM designation from the U.S. FDA, which means that it now has the potential to be integrated with insulin pumps as part of an automated insulin delivery system. Senseonics also recently filed a submission with U.S. regulators for review of our next-generation Eversense 365-day system, and we plan to submit it for regulatory review in Europe soon. Pending clearance, Eversense 365 will offer people with diabetes the possibility to have just one sensor replacement per year, compared to between 26 and 52 for other available CGM systems.
We are resolutely focused on ensuring that we can make Eversense available to as many people as possible. In the U.S., access to Eversense was recently expanded when Medicare policies were updated to include coverage for Eversense for all people with diabetes using insulin. Another important step was introducing the Eversense Remote Patient Monitoring program, which combines long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution. Leveraging this new program, Ascensia and Senseonics have partnered with St. Louis-based Mercy Healthcare Organization, one of the largest healthcare systems in the U.S., on a first-of-its-kind program for diabetes population management. The future looks very bright for Eversense, and for people with diabetes. (As of May 2024)
#1 CGM in Sensor Survivability &
Longevity *6～8
Most Accurate in
Low Glucose Range*6～8
Most Dependable
Detection Alerts*6～8
Almost No Skin Reactions
from Adhesive*9
- *6 Senseonics. (2023) Eversense® E3 Continuous Glucose Monitoring System User Guide. LBL-6002-01-001_Rev C
- *7 Senseonics. (2022) Eversense® E3 Continuous Glucose Monitoring System User Guide. LBL-4002-01-001_Rev B
- *8 Abbott. (2022) FreeStyle Libre 3 Flash Glucose Monitoring System User Manual. ART43911-001 Rev. B 06/22
- *9 Deiss D., et al. Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol & Ther, 2020, 22(1);48-52. DOI: .1089/dia.2019.0159.